Form 4: RA Capital Management Reports Beneficial Ownership Changes in Wave Life Sciences Ltd.

RA Capital Management, along with related entities and individuals, reports changes in beneficial ownership of Wave Life Sciences Ltd. securities due to the grant of restricted share units and options to Dr. Peter Kolchinsky.

Summary

• RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev M. Shah filed a Form 4 detailing changes in their beneficial ownership of Wave Life Sciences Ltd. (WVE) securities.
• The filing reports the grant of 16,115 restricted share units (RSUs) and an option to purchase 32,230 ordinary shares to Dr. Peter Kolchinsky on August 12, 2024, pursuant to the 2024 Non-Employee Director Compensation Policy.
• The RSUs and options vest on the earlier of the Issuer's 2025 annual general meeting or August 12, 2025.
• Dr. Kolchinsky holds the RSUs and options for the benefit of RA Capital Healthcare Fund, L.P., and is obligated to turn over any net cash or shares received to offset advisory fees owed by the Fund to the Adviser.
• RA Capital Management, L.P. is the investment manager for RA Capital Healthcare Fund, L.P., and its general partner is RA Capital Management GP, LLC, of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are managing members.
• The filing indicates that RA Capital Healthcare Fund, L.P. directly holds 18,202,009 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing with no inherent positive or negative sentiment. It simply reports changes in ownership.

Future Outlook

The RSUs and options vest on the earlier of the Issuer's 2025 annual general meeting or August 12, 2025, which could potentially increase the holdings of RA Capital related entities.

Management Comments

• Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund to the Adviser.
• Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a major shareholder and director, which is common in the biotech industry where stock options and RSUs are frequently used as part of compensation packages.

Comparison to Industry Standards

• Director compensation packages including RSUs and options are standard practice in the biotech industry, similar to companies like Alnylam Pharmaceuticals and Sarepta Therapeutics.
• The vesting schedule of the RSUs and options, tied to the annual general meeting or a specific date, is also a common practice to align director interests with shareholder value.

Stakeholder Impact

• The changes in beneficial ownership may have a minor impact on shareholders, as it reflects the compensation structure for directors.
• The vesting of RSUs and options could potentially increase the number of shares outstanding, which may have a dilutive effect.

Key Dates